What is the purpose of Everolimus everbliss 5mg Tablet?
Everolimus everbliss 5mg Tablet is used to treat advanced (late-stage) cancers and noncancerous tumors such as kidney and breast cancer, SEGA (a brain tumor), renal angiomyolipoma (a kidney tumor), and partial-onset seizures (epilepsy) associated with tuberous sclerosis complex (TSC), as well as neuroendocrine tumors.
Is Everolimus everbliss 5mg Tablet associated with weight loss?
- Diarrhea, nausea/vomiting, decreased appetite, weight loss, taste changes, nosebleeds, dry skin, dizziness, and headache are all possible side effects.
- Tell your primary care physician or drug specialist immediately assuming any of these secondary effects endure or deteriorate.
- Pain or sores in the mouth and throat are possible side effects.
When you stop taking Everolimus everbliss 5mg Tablet, what happens?
Do not get any vaccinations (vaccines) while you are taking everolimus or after you stop taking it without your doctor’s permission. Everolimus may weaken your body’s resistance, making the vaccine less effective or causing you to contract the infection that the vaccine is supposed to prevent.
Everolimus everbliss 5mg Tablet is a type of therapy?
Everolimus has a place with the kinase inhibitor class of medications.. Everolimus works by preventing cancer cells from proliferating and reducing the cancer cells’ blood supply. Everolimus reduces transplant rejection by lowering immune system activity.
What is the scientific term for everolimus?
Everolimus, better known by its brand name Afinitor, is a targeted cancer medication that inhibits cancer growth. If you have hormone receptor-positive advanced breast cancer, you may have everolimus.
Is it safe to drink alcohol when taking everolimus?
For the course of your therapy, avoid grapefruit and grapefruit juice because they may interact with everolimus. Alcohol consumption (in tiny doses) appears to have no effect on the safety or effectiveness of everolimus.
Is everolimus a blood pressure medication?
42% of patients treated with everolimus + lenvatinib developed hypertension, compared to 10% of patients treated with everolimus alone and 48% of patients treated with lenvatinib alone.